The incidence of allergies is increasing, particularly in industrialized areas. Allergic inflammation can differ substantially in intensity. Traditional drug therapy such as antihistamines, corticosteroids, anticholinergic agents and leukotriene inhibitors is important in reducing and preventing symptoms and is essential in acute use. More recent therapies including anti-immunoglobin E (IgE) therapy, anti-interleukin (IL) monoclonal antibodies, and phosphodiesterase 4/phospholipaseA2 inhibitors, have improved outcomes. However, in order to develop more effective therapies, further research is needed into the molecular mechanisms underlying allergy onset, particularly in terms of intracellular reactions and the cytosolic Ca2+ balance.
Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.
Our supporting partners do not constitute an endorsement of the content on this page.
Allergic Conditions Content
Expert insights in food allergy: Considerations for diagnosis and management in primary care and beyond
An allergist shares her expert insights on the latest guidance for the diagnosis and management of food allergies, including the role of novel diagnostic tools and emerging therapies in clinical practice.
- Discuss evolving guidance in the prevention and diagnosis of food allergies
- Summarize interdisciplinary strategies for personalizing the management of patients with food allergies
Addressing the diagnosis and management of pet allergies in primary care and beyond
An allergist shares her expert insights and guidance on key clinical questions around the changing paradigm in the diagnosis and management of pet allergies.
- Interpret advances in the diagnosis of pet allergies and how these fit into the current diagnostic paradigm
- Summarize optimal strategies for the management of pet allergies, including effective control measures and treatments
Diagnosing and treating patients with EoE: Tackling the difficulties
Three experts discuss the challenges related to recognizing, diagnosing and treating patients with eosinophilic oesophagitis (EoE) and highlight how advances in diagnostic tools and emerging treatments may impact future care.
- Identify key clinical features of EoE in children and adults
- Explain the diagnostic pathway for EoE and define the usefulness of minimally-invasive tests and tools for diagnosis and monitoring of EoE
- Summarize the efficacy and safety data for biologics in patients with EoE
CRUSE® app, for the management of chronic spontaneous urticaria: Marcus Maurer
The CRUSE® app has been developed for the self-management of chronic spontaneous urticaria (CSU), and to help physicians develop personalised treatment strategies for patients. touchIMMUNOLOGY were delighted to speak with Prof. Marcus Maurer (Professor of Dermatology and Allergy, Charité – Universitätsmedizin Berlin) about the availability, functions, and clinical implications of the app. Questions: Please could you […]
William R. Lumry, AAAAI 2023: Lanadelumab for paediatric patients aged 2 to <12 years with hereditary angioedema – the SPRING Study
The SPRING Study (NCT04070326) was a phase 3 study that investigated the safety, pharmacokinetics, and pharmacodynamics of lanadelumab for prevention of hereditary angioedema (HAE) attacks in children. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the aims, design and findings from the SPRING Study and how […]
William R. Lumry, AAAAI 2023: Current treatment paradigm and unmet needs in hereditary angioedema
Hereditary angioedema (HAE) is a rare genetic disease that reduces C1 inhibitor levels and impacts the regulation of several pathways involved in dilation of the blood vessels and results in recurrent episodes of severe swelling. touchIMMUNOLOGY were delighted to speak with Dr. William R. Lumry (UT Southwestern Medical Center, TX, USA) around the unmet needs […]
Ralph Mösges, AAAAI 2023: Mannan conjugated birch pollen allergoids for the treatment of birch pollen allergy
Mannan conjugated birch pollen allergoids are an immunotherapy currently under clinical investigation for the treatment of birch pollen allergy. touchIMMUNOLOGY caught up with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) to discuss the rationale and methodology of the the clinical trial programme for Mannan conjugated birch pollen allergoids, the efficacy and safety findings so […]
Ralph Mösges, AAAAI 2023: Immunotherapy for the treatment of birch pollen allergy
Allergen immunotherapy aims to treat an allergic response by reducing the production of IgE antibodies by the immune system, this is done by desensitising the patient to the allergen extract. It was a pleasure to talk with Prof. Ralph Mösges (University of Cologne, Cologne, Germany) around the impact immunotherapy has already had on the treatment […]
Luis Felipe C. Ensina, AAAAI 2023: Ligelizumab for the treatment of chronic spontaneous urticaria – findings from PEARL-1 and PEARL-2
Ligelizumab is a monoclonal antibody recently investigated in the phase 3 PEARL-1 and PEARL-2 studies for the treatment of chronic spontaneous urticaria (ClinicalTrials.gov Identifiers: NCT03580369 & NCT03580356). In this touchIMMUNOLOGY interview, we spoke with Dr. Luis Felipe C. Ensina (Federal University of São Paulo, São Paulo, Brazil) around the rationale for investigating ligelizumab in this […]